Health ProductsPublic Communication

VECTIBIX (panitumumab) - Rare Cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis - For the Public

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Biologic/vaccine
Issue: Important Safety Information
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Amgen Canada Inc. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

PUBLIC COMMUNICATION - Health Canada Endorsed Important Safety Information on VECTIBIX (panitumumab)

May 27, 2014

Subject: Rare cases of severe skin reactions called Stevens-Johnson syndrome and Toxic Epidermal Necrolysis have been reported in patients treated with VECTIBIX®(panitumumab)

Amgen Canada Inc., in consultation with Health Canada, would like to inform you of important new safety information related to severe skin reactions called Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) reported in regard to VECTIBIX®.

VECTIBIX is used to treat certain types of cancer of the colon and/or rectum that have spread to other parts of the body. VECTIBIX has been approved with conditions, pending the results of studies to verify its clinical benefit.

Stevens-Johnson Syndrome (SJS) and TEN are severe body surface reactions which may extend from the skin to involve the lining of the mouth, the anal and genital area, as well as the inside lining of the eyelids. These reactions can sometimes lead to death.

  • Cases of SJS and TEN have been reported rarely (≥1/10,000 patients and <1/1000 patients) in patients treated with VECTIBIX.
  • Signs and symptoms of SJS and TEN may include blistering of the skin, mouth, eyes and genitals. One or many of these symptoms may occur up to 7-14 days after an infusion of VECTIBIX.
  • If you experience any of these symptoms, or if you have any questions regarding SJS or TEN, please contact your doctor immediately.

Amgen Canada is working with Health Canada to update the safety information for VECTIBIX and has sent a letter to health care professionals to inform them of this new important safety information. A copy of that letter is available on the Health Canada Web site. This information is also available at www.amgen.ca.

Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of serious skin reactions called Stevens-Johnson syndrome and Toxic Epidermal Necrolysis or other serious or unexpected side effects in patients receiving VECTIBIX should be reported to Amgen Canada Inc. or Health Canada.

Amgen Canada Inc.
6775 Financial Drive, Suite 100
Mississauga, Ontario L5N 0A4
Safety Tel: 1-866-512-6436 or Fax: 1-888-264-3655
Safety e-mail: safetycanada@amgen.com

You can report any suspected side effect associated with the use of health products to Health Canada by:

  • Calling toll-free at 1-866-234-2345; or
  • Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.

For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

Sincerely,

original signed by

Clive Ward-Able, MD
Executive Medical Director
Amgen Canada Inc.

For more information

Through surveillance, the manufacturer identified a risk associated with the product and has submitted to Health Canada an update to its product label to reflect the findings. The label changes have been reviewed and approved by Health Canada. A comprehensive internal signal assessment was not required for this issue, and therefore a Summary Safety Review is not available.
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime